- Research article
- Open Access
- Open Peer Review
A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer
© Pértega-Gomes et al.; licensee BioMed Central Ltd. 2014
- Received: 20 November 2013
- Accepted: 12 May 2014
- Published: 21 May 2014
In a malignant tumour, cancer cells are embedded in stromal cells, namely cancer-associated fibroblasts (CAFs). These CAFs are now accepted as important players in cancer dynamics, being involved in tumour growth and progression. Although there are various reports on the interaction between tumour and stromal cells, the clinico-pathological significance of this cross-talk is still largely unknown. In this study, we aimed to characterise the expression of key metabolic proteins involved in glucose transport, pyruvate/lactate shuttle system, glycolytic metabolism and fatty acid oxidation in CAFs and tumour cells in different stages of malignant transformation. We further aimed to contextualise the clinico-pathological significance of these protein expression profiles with reference to known prognostic indicators, including biochemical recurrence in pT stage.
Prostate tissues were obtained from 480 patients with a median age of 64 years following radical prostatectomy with no previous hormonal therapy. Tissues were analysed for the expression of several key metabolism-related proteins in glands and surrounding fibroblasts by immunohistochemistry. Reliable markers of prognosis such as pT stage and biochemical recurrence were assessed for each case.
We observed that prostate cancer cells did not rely mainly on glycolytic metabolism, while there was a high expression of MCT4 and CAIX - in CAFs. This corroborates the hypothesis of the “Reverse Warburg effect” in prostate cancer, in which fibroblasts are under oxidative stress and express CAIX, an established hypoxia marker. We found that alterations in the expression of metabolism-related proteins were already evident in the early stages of malignant transformation, suggesting the continuing alteration of CAFs from an early stage. Additionally, and for the first time, we show that cases showing high MCT4 expression in CAFs with concomitant strong MCT1 expression in prostate cancer (PCa) cells are associated with poor clinical outcome, namely pT3 stage of the tumour.
In summary, this work demonstrates for the first time the clinico-pathological significance of the lactate shuttle in prostate cancer. It also suggests that other alterations in CAFs may be useful prognostic factors, and further supports the use of MCT1/MCT4 as targets for PCa therapy.
- Monocarboxylate transporters
- Cancer associated fibroblasts
- Poor prognosis
- Prostate cancer
It is well established that solid tumours, including prostate cancer, exist under fluctuating oxygen tension, during which they are intermittently exposed to hypoxia [1, 2]. Under hypoxic conditions, tumour cells primarily use glycolysis for energy, producing lactate, which is expelled to the tumour microenvironment, allowing tumours to continue their glycolytic activity [3, 4]. Recently, Sonveaux et al. showed that lactate, which is generally considered a waste product, is preferred over glucose by oxidative tumour cells as their primary energy source .
Monocarboxylate transporters (MCTs) have been shown to play an important role in various tumours . However, since they facilitate the transport of lactate in and out of cells, their role in this stromal/epithelial cell symbiosis is also attracting interest. MCT1 is a high-affinity transporter and its expression seems to be regulated by multiple signalling pathways, micro-environmental parameters, changes in substrate concentration and pH . MCT4 is a low-affinity transporter, which is abundant in highly glycolytic muscle cells and is one of the many target genes of hypoxia-inducible factor 1 alpha (HIF-1α) . Other targets of HIF-1α include glucose transporter-1 (GLUT-1), the main transporter involved in glucose uptake [9, 10]; lactate dehydrogenase V (LDHV), which is responsible for the conversion of pyruvate into lactate; pyruvate dehydrogenase kinase isozyme 1 (PDK1), which is responsible for the phosphorylation and consequent inactivation of pyruvate dehydrogenase (PDH); and carbonic anhydrase IX (CAIX), a hypoxia-related protein involved in pH regulation . Alpha-methylacyl-CoA racemase (AMACR), pristanoyl-CoA oxidase (ACOX-3) and D-bifunctional protein (DBP), are also important fatty acid oxidation-related proteins in prostate cancer [12, 13], and we also included them in our analysis.
The importance of a lactate shuttle system between cancer cells and surrounding stroma has been described in various tumour types [14–16], but its significance in prostate cancer is not clear [17, 18].
In this study, we aimed to identify a metabolic interaction between CAFs and prostate cancer cells, by analysing the expression of key metabolism-related proteins in CAFs in relation to prostate cancer using prostate tissue samples. We also assessed the clinico-pathological significance of this expression to investigate a possible CAF signature for PCa progression.
Patient sample selection
Formalin–fixed paraffin embedded tissues from 480 prostate cancer patients were retrieved from the archives of the Department of Pathology of Centro Hospitalar do Porto, Portugal. Stroma surrounding non-neoplastic glands, prostatic intra-epithelial hyperplasia (PIN) lesions and malignant glands were also analysed. Prostate cancer patients were selected for the study according to the following criteria: availability of both tumour and normal tissue for each patient, presence of adequate amount of stroma in both normal and tumour tissues for efficient selection for tissue microarray construction (TMA), and absence of chemotherapy or radiotherapy. Prior to TMA construction, tissue morphology was assessed on HE slides. Data for clinical parameters significant in patient outcome were available, including pre-operative serum total PSA, clinical stage, perineural invasion and biochemical recurrence.
The work has been approved by DEFI (Departamento de Ensino Formação e Investigação) Ethics Committee of Centro Hospitalar do Porto ref. no. 017/08(010-DEFI/015-CES).
Details of the immunohistochemical procedure used to analyze the expression of the different proteins
Santa Cruz Biotechnology
R.T.U. Vectastain Universal Elite ABC Kit, Vector, EUA
Head and neck tumor
Ultravision Detection System Anti-polyvalent, HRP, Labvision Corporation, Freemont, CA
Santa Cruz Biotechnology
R.T.U. Vectastain Universal Elite ABC Kit, Vector, EUA
Santa Cruz Biotechnology
Ultravision Detection System Anti-polyvalent, HRP, Labvision Corporation, Freemont, CA
DBP antibody was a gift from Dr. Gabriele Moller from HelmholtzZentrum mÜnchen
Ready to use
IHC evaluation was performed as previously described  and scored independently by two pathologists (JRV, CL), blinded to the target under study. For statistical purposes, only moderate and strong immunoreaction final scores were considered positive. Discordant cases were discussed in order to agree on a final score.
Key metabolism-related proteins in fibroblasts and prostate glands across malignant transformation, i.e. from BAFs to PAFs and finally CAFs, were investigated. MCT1 was clearly expressed in the plasma membrane of prostate glands, but not the surrounding stroma. In contrast, the expression of MCT4 increased in fibroblasts with increasing degree of malignant transformation, but not in the prostate glands. PDK1 expression was detected in both glands and stroma, whereas CAIX was only detected in stroma, with no staining in prostate glands (Figure 3).
Correlations between the key metabolic-related proteins MCT4, PDK1 and CAIX expressions in CAFs and clinico-pathological data
Several research groups have recently focused on the role of CAFs in the progression and metastasis of prostate cancer, showing that a dynamic interaction between stroma and epithelium might play a critical role in this progression [14, 15, 22–25]. Thus, the essential role played by the cross-talk between stroma and epithelium in carcinogenesis and prostate cancer progression has been increasingly recognised. In this work, we provide evidence for the possible metabolic co-operation between cancer cells and the surrounding fibroblasts by examining the expression of major proteins involved in cellular metabolism. In particular, we focus on differences between cancer cells and tumour-associated fibroblasts, as well as between fibroblasts in different stages of malignant transformation, and examine the possible clinico-pathological significance of the expression of these proteins.
By categorising the protein expression of stromal cells associated with prostate cancer, we describe a compartment that is not well studied and will contribute to an improved understanding of prostate cancer. We observed significant differences between CAFs and tumour glands with respect to the expression of key metabolic proteins. In particular, CAIX and MCT4 selectively labelled cancer associated fibroblasts in contrast to malignant glands, where CAIX and MCT4 were only present in very few cases. On the other hand, a distinct, strong membranous expression of MCT1 was consistently observed in cancer cells, suggesting a role for MCT1 in the transport of lactate into tumour cells from the acidic extracellular matrix, suggesting that lactate might be used as a fuel by oxidative cancer cells. We also observed that proteins involved in fatty acid oxidation, such as AMACR, ACOX-3 and DBP, were restricted to the tumour cells, which is consistent with the presence of a metabolic pathway different from glycolysis, and compatible with oxidative phosphorylation in prostate cancer cells. It is important to note that fatty acid oxidation is already considered a major source of acetyl-CoA for the Krebs cycle , which further supports our hypothesis.
The expression levels of GLUT1, a key glucose transporter, define the rates of glucose influx into the cells. In the present study, CAFs did not show GLUT1 or GLUT-12 expression, and LDHV was also difficult to detect. However, this possibly reflects the limits of the immunohistochemical technique to detect these proteins at the baseline concentrations present in CAFs. Indeed, we have previously found very few cases positive for GLUT-1 and GLUT-12, and this expression was not present at the plasma membrane, suggesting a low level of activity of these proteins in prostate cancer cells (unpublished results). Thus, assessment of other GLUT isoforms may be worthwhile.
Interestingly, we also observed that protein expression of MCT4, PDK1 and CAIX in prostate fibroblasts changes during malignant transformation, suggesting that the existing stroma might also suffer alterations and play a role in this metabolic adaptation of cancer cells beyond the well-studied role of newly formed stroma.
From the above immunohistochemical findings, it seems that well-organised metabolic regions composed of tumour cells and CAFs may contribute to the ability of the tumour to overcome the adverse microenvironment.
Our hypothesis is in agreement with those of Fiaschi et al., who describe the metabolic reprogramming of CAFs towards the Warburg phenotype as a result of contact with prostate cancer cells. Using in vitro studies, they showed lactate production and efflux by de novo expressed MCT4 in CAFs and also demonstrated that, upon contact with CAFs, prostate cancer cells were reprogrammed towards aerobic metabolism, with an increase in lactate uptake via the lactate transporter MCT1. Furthermore, pharmacological inhibition of MCT1-mediated lactate uptake dramatically affected PCa cell survival and tumour outgrowth. However, in this study, no data regarding clinico-pathological associations were shown, and few cases were assessed. These findings are in contrast with others (, which describe an energy recycling path between the aerobic stroma and the anaerobic cancer cells within the framework of the Warburg effect. These conclusions are based mainly on the observation that LDH1 is evidently expressed in CAFs, and the presence of MCT1 in prostate cancer cells was attributed to its role in lactate efflux and not its uptake. We recognise the importance of assessing LDH1; however, in our study we assessed for the first time MCT4 and CAIX as important markers of hypoxia in a larger cohort. Our findings corroborate the work of Whitaker-Menezes et al., who described a “reverse Warburg effect,” where CAFs undergo aerobic glycolysis to produce lactate, which is subsequently used as a metabolic substrate by adjacent cancer cells. In this model, “energy transfer” or “metabolic coupling” between the tumour stroma and epithelial cancer cells fuels tumour growth and metastasis via oxidative mitochondrial metabolism in anabolic cancer cells. We believe that this is also the case in prostate cancer, although more studies are needed to demonstrate this.
Also, we assessed important clinico-pathological parameters and found significant associations with poor prognosis, raising once more the possible role of CAFs in disease management. We believe that these changes are likely to be a by-product of tumour biology with further influence on patient outcomes that need to be explored more deeply.
In summary, we show for the first time that there is a clinico-pathological significance for the MCT1/MCT4 lactate shuttle in prostate cancer. In fact, it seems that the stromal expression of hypoxia-regulated proteins is an adverse prognostic factor in prostate carcinomas, suggesting that tumour hypoxia may influence tumour-associated stromal cells in a way that ultimately contributes to patient prognosis.
NPG received a fellowship from the Portuguese Foundation for Science and Technology (FCT), refs. SFRH/BD/61027/2009. This work was supported by the FCT grant ref. PTDC/ SAUMET/113415/2009, under the scope of “Programa Operacional Temático Factores de Competitividade” (COMPETE) of “Quadro Comunitário de Apoio III” and co-financed by Fundo Comunitário Europeu FEDER. JA was supported by a Boehringer Ingelheim Fonds fellowship.
- Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC: The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int. 2010, 105 (1): 8-13.View ArticlePubMedGoogle Scholar
- Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Pinover WH, Greenberg RE, Stobbe C, Hanks GE: Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. Am J Clin Oncol. 2001, 24 (5): 458-61.View ArticlePubMedGoogle Scholar
- Helmlinger G, Yuan F, Dellian M, Jain RK: Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med. 1997, 3 (2): 177-82.View ArticlePubMedGoogle Scholar
- Tannock IF, Rotin D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989, 49 (16): 4373-84.PubMedGoogle Scholar
- Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Dieport C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008, 118 (12): 3930-42.PubMedPubMed CentralGoogle Scholar
- Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Scmitt FC, Baltazar F: Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr. 2012, 44 (1): 127-39.View ArticlePubMedGoogle Scholar
- Enerson BE, Drewes LR: Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J Pharm Sci. 2003, 92 (8): 1531-44.View ArticlePubMedGoogle Scholar
- Halestrap AP, Wilson MC: The monocarboxylate transporter family–role and regulation. IUBMB Life. 2012, 64 (2): 109-19.View ArticlePubMedGoogle Scholar
- Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, Overgaard J: Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer. 2008, 122 (12): 2726-34.View ArticlePubMedGoogle Scholar
- Semenza GL: Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol. 2009, 19 (1): 12-6.View ArticlePubMedGoogle Scholar
- Potter CP, Harris AL: Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer. 2003, 89 (1): 2-7.View ArticlePubMedPubMed CentralGoogle Scholar
- Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB: Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate. 2005, 63 (4): 316-23.View ArticlePubMedGoogle Scholar
- Liu Y: Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006, 9 (3): 230-4.View ArticlePubMedGoogle Scholar
- Koukourakis MI, Giatromanolaki A, Bougioukas G, Sivridis E: Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther. 2007, 6 (9): 1476-9.View ArticlePubMedGoogle Scholar
- Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E: Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006, 66 (2): 632-7.View ArticlePubMedGoogle Scholar
- Whitaker-Menezes , Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, Birbe RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, Philp NG, Lisanti MP: Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle. 2011, 10 (11): 1772-83.View ArticlePubMedPubMed CentralGoogle Scholar
- Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, Chiarugi P: Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 2012, 72 (19): 5130-40.View ArticlePubMedGoogle Scholar
- Giatromanolaki A, Koukourakis MI, Koutsopoulos A, Mendrinos S, Sivridis E: The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol Ther. 2012, 13 (13): 1284-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Pertega-Gomes A, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F: Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer. 2011, 11: 312-View ArticlePubMedPubMed CentralGoogle Scholar
- Cooper RP, Aslin RN: The language environment of the young infant: implications for early perceptual development. Can J Psychol. 1989, 43 (2): 247-65.View ArticlePubMedGoogle Scholar
- Cramblit NS, Siegel GM: The verbal environment of a language-impaired child. J Speech Hear Disord. 1977, 42 (4): 474-82.View ArticlePubMedGoogle Scholar
- Condon MS: The role of the stromal microenvironment in prostate cancer. Semin Cancer Biol. 2005, 15 (2): 132-7.View ArticlePubMedGoogle Scholar
- Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR: Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005, 65 (19): 8887-95.View ArticlePubMedGoogle Scholar
- Arnold JT, Gray NE, Jacobowitz K, Viswanathan L, Cheung PW, McFann KK, Le H, Blackman MR: Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. J Steroid Biochem Mol Biol. 2008, 111 (3–5): 240-6.View ArticlePubMedPubMed CentralGoogle Scholar
- Morrissey C, Vessella RL: The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem. 2007, 101 (4): 873-86.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/352/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.